Profile data is unavailable for this security.
About the company
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
- Revenue in USD (TTM)0.00
- Net income in USD-120.74m
- Incorporated2016
- Employees140.00
- LocationTenaya Therapeutics Inc171 Oyster Point Blvd., Suite 500SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 865-2066
- Fax+1 (302) 655-5049
- Websitehttps://www.tenayatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardiff Oncology Inc | 665.00k | -40.88m | 127.55m | 31.00 | -- | 2.39 | -- | 191.80 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Sagimet Biosciences Inc | 2.00m | -29.25m | 127.65m | 10.00 | -- | 0.6904 | -- | 63.83 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Puma Biotechnology Inc | 219.14m | 8.72m | 128.50m | 185.00 | 14.31 | 2.62 | 6.33 | 0.5864 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
P3 Health Partners Inc | 1.40bn | -69.48m | 129.46m | 400.00 | -- | 0.3509 | -- | 0.0923 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
TriSalus Life Sciences Inc | 24.74m | -57.21m | 129.56m | 112.00 | -- | -- | -- | 5.24 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
PDS Biotechnology Corp | 0.00 | -40.68m | 131.08m | 25.00 | -- | 4.23 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
Actuate Therapeutics Inc | -100.00bn | -100.00bn | 135.74m | 11.00 | -- | -- | -- | -- | -- | -- | -- | -1.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -22.74 | -- | -- | -- |
Vigil Neuroscience Inc | 0.00 | -83.84m | 136.39m | 64.00 | -- | 1.52 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -120.74m | 136.48m | 140.00 | -- | 1.02 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Kodiak Sciences Inc | 0.00 | -197.68m | 139.43m | 111.00 | -- | 0.65 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Context Therapeutics Inc | 0.00 | -18.57m | 139.50m | 5.00 | -- | 1.38 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Immunic Inc | 0.00 | -95.31m | 140.52m | 77.00 | -- | 2.21 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 141.79m | 51.00 | -- | 0.5812 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
Ventyx Biosciences Inc | 0.00 | -171.30m | 144.87m | 73.00 | -- | 0.5159 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
Repare Therapeutics Inc | 68.68m | -68.52m | 146.44m | 179.00 | -- | 0.719 | -- | 2.13 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Holder | Shares | % Held |
---|---|---|
Casdin Capital LLCas of 31 Mar 2024 | 6.73m | 8.58% |
RA Capital Management LPas of 31 Mar 2024 | 5.76m | 7.33% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.22m | 4.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.92m | 3.71% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.91m | 3.71% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 2.85m | 3.64% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.81m | 3.57% |
Integral Health Asset Management LLCas of 31 Mar 2024 | 2.25m | 2.87% |
Citadel Advisors LLCas of 31 Mar 2024 | 2.24m | 2.86% |
BlackRock Advisors LLCas of 31 Mar 2024 | 1.58m | 2.02% |